CardiOR s.r.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At CardiOR s.r.o. in Trencin, clinical research in cardiovascular medicine focuses on reducing the risk of serious heart and vascular events in people with elevated risk profiles. The studies are centered on common conditions such as atherosclerotic cardiovascular disease, stable angina pectoris, and adults at high risk of coronary events without a prior heart attack or stroke.
- Evaluating new treatments intended to lower the risk of heart disease death, myocardial infarction, and ischemic stroke
- Assessing therapies aimed at improving outcomes in people with high cardiovascular risk despite optimized standard care
- Studying approaches that may help prevent urgent coronary revascularization and other major cardiac events
Overall, the site is contributing to research that tests whether emerging cardiovascular therapies can better protect patients from major complications and improve long-term heart health.
Nutritional and Metabolic Diseases
Research at this hospital/clinic also extends into nutritional and metabolic disease areas, especially conditions linked to abnormal blood lipids and inherited risk factors. The main focus is on patients with elevated lipoprotein(a) and related forms of cardiovascular risk that can contribute to future heart problems.
- Testing whether targeted treatment can improve outcomes in people with elevated lipoprotein(a)
- Exploring therapies designed to reduce the chance of coronary heart disease events in ASCVD
- Supporting research into lipid-related risk reduction for patients already receiving standard lipid-lowering therapy
These studies aim to clarify whether newer treatment strategies can better address metabolic contributors to cardiovascular disease and help lower future event rates.
Stable Angina and Anti-anginal Research
The site is also involved in clinical trials for stable angina pectoris, a condition marked by chest discomfort caused by reduced blood flow to the heart. This line of research is designed to confirm the effectiveness of treatments that may relieve symptoms and improve daily functioning for patients living with chronic angina.
- Confirming the anti-anginal effect of a new therapy in patients with chronic symptoms
- Evaluating whether treatment can improve control of chest pain and related discomfort
- Advancing options for people whose stable coronary disease continues to affect quality of life
By focusing on symptom relief and treatment benefit, this research supports better care for patients with ongoing ischemic heart disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Tasly Pharmaceuticals Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CardiOR s.r.o.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Effect of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a): A Randomized, Placebo-Controlled Study | Amgen Inc. | Phase III | Not Recruiting | May 2023 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Evolocumab | 1 | Unknown | 2019-05-24 | 2019-05-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.